Abstract

INTRODUCTION
Severe asthma means asthma that is uncontrolled despite adherence with maximal optimized
therapy and treatment of contributory factors, or that worsens when high dose treatment is
decreased. Mepolizumab arises as an asthma treatment in step 5 of GINA.
The objective of the study was to assess the evolution of the levels of eosinophils, FeNO and FEV1
after the start of Mepolizumab.
METHODS
It is a prospective study of patients who have started treatment with mepolizumab in our asthma
office. We collected different variables before and after the start of mepolizumab.
RESULTS
19 patients have been collected, of which 78.9% (15) were women, with an average age of 51.9
years and an average IgE level of 85.84.

Table 1 shows the average evolutionary values of the variables collected.

_{Table 1}

Figure 1 shows the evolution of these variables over time.

_{Figure 1}

CONCLUSIONS
-The use of mepolizumab improves lung function and FENO levels with a reduction in the number of
eosinophils, with the consequent subjective clinical improvement.
-Given the data, it is expected that in the annual control the tendency to improve these patients will
be confirmed